MKKGY Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 12.31% compared to Merck KGaA's net margin of -227.46%. Merck KGaA's return on equity of 9.8% beat BioNTech SE's return on equity of -3.91%.

Merck KGaA has a consensus price target of $37.10, signalling upside risk potential of 34.76%. On the other hand BioNTech SE has an analysts' consensus of $136.23 which suggests that it could grow by 46.8%. Given that BioNTech SE has higher upside potential than Merck KGaA, analysts believe BioNTech SE is more attractive than Merck KGaA.

Merck KGaA has a beta of 0.992, which suggesting that the stock is 0.801% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.347, suggesting its more volatile than the S&P 500 by 34.675%.

Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.82%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.23% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.8B, which are larger than BioNTech SE quarterly revenues of $192.3M. Merck KGaA's net income of $711M is higher than BioNTech SE's net income of -$437.5M. Notably, Merck KGaA's price-to-earnings ratio is 19.86x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.61x versus 7.52x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of 12.31% compared to Merck KGaA's net margin of 68.44%. Merck KGaA's return on equity of 9.8% beat CureVac NV's return on equity of 21.3%.

Merck KGaA has a consensus price target of $37.10, signalling upside risk potential of 34.76%. On the other hand CureVac NV has an analysts' consensus of $6.24 which suggests that it could grow by 78.76%. Given that CureVac NV has higher upside potential than Merck KGaA, analysts believe CureVac NV is more attractive than Merck KGaA.

Merck KGaA has a beta of 0.992, which suggesting that the stock is 0.801% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.82%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.23% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.8B, which are larger than CureVac NV quarterly revenues of $543.2M. Merck KGaA's net income of $711M is higher than CureVac NV's net income of $371.8M. Notably, Merck KGaA's price-to-earnings ratio is 19.86x while CureVac NV's PE ratio is 4.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.61x versus 1.33x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

Fresenius Medical Care AG has a net margin of 12.31% compared to Merck KGaA's net margin of 3.1%. Merck KGaA's return on equity of 9.8% beat Fresenius Medical Care AG's return on equity of 4.05%.

Merck KGaA has a consensus price target of $37.10, signalling upside risk potential of 34.76%. On the other hand Fresenius Medical Care AG has an analysts' consensus of $26.60 which suggests that it could fall by -5.79%. Given that Merck KGaA has higher upside potential than Fresenius Medical Care AG, analysts believe Merck KGaA is more attractive than Fresenius Medical Care AG.

Merck KGaA has a beta of 0.992, which suggesting that the stock is 0.801% less volatile than S&P 500. In comparison Fresenius Medical Care AG has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.616%.

Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.82%. Fresenius Medical Care AG offers a yield of 2.28% to investors and pays a quarterly dividend of $0.64 per share. Merck KGaA pays 10.23% of its earnings as a dividend. Fresenius Medical Care AG pays out 64.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.8B, which are larger than Fresenius Medical Care AG quarterly revenues of $5.1B. Merck KGaA's net income of $711M is higher than Fresenius Medical Care AG's net income of $159.1M. Notably, Merck KGaA's price-to-earnings ratio is 19.86x while Fresenius Medical Care AG's PE ratio is 24.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.61x versus 0.79x for Fresenius Medical Care AG. Usually stocks with elevated PS ratios are considered overvalued.

Siemens Healthineers AG has a net margin of 12.31% compared to Merck KGaA's net margin of 8.65%. Merck KGaA's return on equity of 9.8% beat Siemens Healthineers AG's return on equity of 10.69%.

Merck KGaA has a consensus price target of $37.10, signalling upside risk potential of 34.76%. On the other hand Siemens Healthineers AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Merck KGaA has higher upside potential than Siemens Healthineers AG, analysts believe Merck KGaA is more attractive than Siemens Healthineers AG.

Merck KGaA has a beta of 0.992, which suggesting that the stock is 0.801% less volatile than S&P 500. In comparison Siemens Healthineers AG has a beta of 1.060, suggesting its more volatile than the S&P 500 by 6.049%.

Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.82%. Siemens Healthineers AG offers a yield of 3.81% to investors and pays a quarterly dividend of $0.50 per share. Merck KGaA pays 10.23% of its earnings as a dividend. Siemens Healthineers AG pays out 54.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.8B, which are smaller than Siemens Healthineers AG quarterly revenues of $5.8B. Merck KGaA's net income of $711M is higher than Siemens Healthineers AG's net income of $505.3M. Notably, Merck KGaA's price-to-earnings ratio is 19.86x while Siemens Healthineers AG's PE ratio is 27.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.61x versus 2.40x for Siemens Healthineers AG. Usually stocks with elevated PS ratios are considered overvalued.